WA
UTHR icon

Whipplewood Advisors’s United Therapeutics UTHR Stock Holding History

Whipplewood Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11
Closed -$6.52K – 1014
2026
Q1 		$6.52K Buy
+11
New +$5.48K ﹤0.01% 563
2025
Q3 		– Sell
-22
Closed -$6.32K – 1123
2025
Q2 		$6.32K Buy
22
+7
+47% +$2.09K ﹤0.01% 651
2025
Q1 		$6.78K Sell
15
-7
-32% -$2.4K ﹤0.01% 638
2024
Q4 		$7.76K Buy
+22
New +$8.09K ﹤0.01% 601

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Whipplewood Advisors's UTHR Position: Q2 2026 in Review

Whipplewood Advisors sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 11 shares — an estimated $6.52K sold.

Whipplewood Advisors first reported a position in UTHR in Q4 2024 and held it in 4 quarters. The position peaked at $7.76K in Q4 2024. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Whipplewood Advisors reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Whipplewood Advisors sold 11 United Therapeutics shares in Q2 2026, an estimated $6.52K.
  • Whipplewood Advisors first reported a position in United Therapeutics in Q4 2024 and held it in 4 quarters.
  • Whipplewood Advisors's United Therapeutics position peaked at $7.76K in Q4 2024.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.